​

Recursion Pharmaceuticals (RXRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RXRX Stock Forecast

Recursion Pharmaceuticals (RXRX) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $6.00, with a high of $6.00 and a low of $6.00. This represents a 4.17% increase from the last price of $5.76.

$5 $6 $7 $8 $9 $10 $11 $12 $13 $14 High: $6 Avg: $6 Low: $6 Last Closed Price: $5.76

RXRX Stock Rating

Recursion Pharmaceuticals stock's rating consensus is Hold, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (33.33%), 6 Hold (66.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 9 0 6 3 Strong Sell Sell Hold Buy Strong Buy

RXRX Price Target Upside V Benchmarks

TypeNameUpside
StockRecursion Pharmaceuticals4.17%
SectorHealthcare Stocks 35.46%
IndustryBiotech Stocks 87.81%

Price Target Trends

1M3M12M
# Anlaysts-15
Avg Price Target-$6.00$10.20
Last Closing Price$5.76$5.76$5.76
Upside/Downside-4.17%77.08%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25116--8
Mar, 25116--8
Feb, 25116--8
Jan, 25116--8
Dec, 24116--8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 28, 2025Leerink Partners$6.00$7.51-20.11%4.17%
Sep 04, 2024Gil BlumNeedham$11.00$6.1080.33%90.97%
Sep 03, 2024Scott SchoenhausKeyBanc$12.00$6.0797.69%108.33%
Sep 03, 2024Dennis DingJefferies$6.00$6.02-0.33%4.17%
Jun 26, 2024Scott SchoenhausKeyBanc$16.00$8.7682.65%177.78%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 28, 2025Cowen & Co.HoldHoldhold
Sep 04, 2024NeedhamMarket PerformMarket Performhold
Sep 04, 2024NeedhamBuyBuyhold
Sep 03, 2024KeyBancOverweightOverweighthold
Sep 03, 2024Cowen & Co.HoldHoldhold
Sep 03, 2024JefferiesHoldHoldhold
Jun 26, 2024KeyBancOverweightOverweighthold
May 10, 2024NeedhamBuyBuyhold
Apr 09, 2024NeedhamBuyBuyhold
Mar 04, 2024NeedhamBuyBuyhold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.05$-1.36$-1.58$-1.69----
Avg Forecast$-1.19$-1.41$-1.65$-1.54$-1.65$-1.38$-1.12$-0.95
High Forecast$-0.39$-0.42$-1.59$-1.45$-1.49$-0.17$-0.14$-0.12
Low Forecast$-2.42$-2.57$-1.73$-1.63$-1.85$-2.85$-2.32$-1.97
Surprise %-11.76%-3.55%-4.24%9.74%----

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.00M$39.68M$44.58M$58.84M----
Avg Forecast$12.32M$48.26M$52.14M$70.75M$92.56M$123.79M$143.40M$194.30M
High Forecast$22.09M$78.87M$60.00M$85.45M$147.23M$225.66M$261.40M$354.19M
Low Forecast$5.98M$22.19M$43.58M$63.61M$44.06M$40.35M$46.74M$63.33M
Surprise %-18.86%-17.78%-14.51%-16.83%----

Net Income Forecast

$-600M $-480M $-360M $-240M $-120M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-178.07M$-239.42M$-328.07M$-463.66M----
Avg Forecast$-247.35M$-292.38M$-344.74M$-319.83M$-346.84M$-347.15M$-232.80M$-197.46M
High Forecast$-81.84M$-87.01M$-330.46M$-301.50M$-309.38M$-35.40M$-28.80M$-24.43M
Low Forecast$-502.09M$-533.44M$-359.02M$-338.17M$-384.31M$-592.26M$-481.84M$-408.70M
Surprise %-28.01%-18.11%-4.84%44.97%----

RXRX Forecast FAQ

Is Recursion Pharmaceuticals stock a buy?

Recursion Pharmaceuticals stock has a consensus rating of Hold, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 6 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Recursion Pharmaceuticals is a neutral investment for most analysts.

What is Recursion Pharmaceuticals's price target?

Recursion Pharmaceuticals's price target, set by 9 Wall Street analysts, averages $6 over the next 12 months. The price target range spans from $6 at the low end to $6 at the high end, suggesting a potential 4.17% change from the previous closing price of $5.76.

How does Recursion Pharmaceuticals stock forecast compare to its benchmarks?

Recursion Pharmaceuticals's stock forecast shows a 4.17% upside, underperforming the average forecast for the healthcare stocks sector (35.46%) and underperforming the biotech stocks industry (87.81%).

What is the breakdown of analyst ratings for Recursion Pharmaceuticals over the past three months?

  • April 2025: 12.50% Strong Buy, 12.50% Buy, 75.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 12.50% Strong Buy, 12.50% Buy, 75.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 12.50% Strong Buy, 12.50% Buy, 75.00% Hold, 0% Sell, 0% Strong Sell.

What is Recursion Pharmaceuticals’s EPS forecast?

Recursion Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.65, marking a -2.37% decrease from the reported $-1.69 in 2024. Estimates for the following years are $-1.38 in 2026, $-1.12 in 2027, and $-0.95 in 2028.

What is Recursion Pharmaceuticals’s revenue forecast?

Recursion Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $92.56M, reflecting a 57.31% increase from the reported $58.84M in 2024. The forecast for 2026 is $123.79M, followed by $143.4M for 2027, and $194.3M for 2028.

What is Recursion Pharmaceuticals’s net income forecast?

Recursion Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-347M, representing a -25.19% decrease from the reported $-464M in 2024. Projections indicate $-347M in 2026, $-233M in 2027, and $-197M in 2028.